admin, Author at Integral Molecular

Published by

A Shot in the Arm for Flu Research: Integral Molecular Introduces Off-the-Shelf Reagents to Evaluate 2023/2024 Influenza Vaccine Efficacy

PHILADELPHIA–Integral Molecular, a leader in providing safe, off-the-shelf Reporter Virus Particles (RVPs) to study vaccine efficacy, has expanded its extensive portfolio with RVPs for […]

Published by

Genetic Engineering and Integral Molecular Present – Specificity Testing of Antibody and CAR-T Cell Therapies for IND Using the Membrane Proteome Array

Thursday, June 22, 2023 8 am PT, 11 am ET, 17:00 CET Register now Rigorous specificity analysis is critical for successful drug development […]

Published by

Integral Molecular Opens New Research Center in Philadelphia Encompassing Pandemic Preparedness Laboratories

PHILADELPHIA–Integral Molecular, a founding member of Philadelphia’s biotech community, announces the official opening of its 32,000 square foot headquarters and integrated research facilities that […]

Published by

Integral Molecular Reveals Mechanism Underlying Exquisite Specificity of Claudin 6 Therapeutic Antibody Being Developed for Solid Tumors

PHILADELPHIA–Integral Molecular, the industry leader in antibody discovery for membrane proteins, has published the targeting mechanism enabling best-in-class specificity of its Claudin 6 (CLDN6) […]

Published by

Integral Molecular Partnership: Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors

CTIM-76 named as lead candidate to target Claudin 6 positive cancers IND submission expected in Q1 2024 Context to host webinar on Thursday, December […]

Published by

Integral Molecular Launches New Product Lines of Safe Reporter Viruses for Vaccine Development and Pandemic Preparedness

PHILADELPHIA–Using its extensive experience gained fighting COVID-19 and other virus threats for over 20 years, Integral Molecular has launched an expanded collection of its […]

Published by

Genetic Engineering and Integral Molecular Present – Reporter Virus Tools to Combat Current Viral Threats and the Next Pandemic

Thursday, November 10, 2022 Watch the webinar The COVID-19 pandemic has brought virology to the forefront of many research programs. But how do […]

Published by

Integral Molecular Licenses Claudin 18.2 Monoclonal Antibodies to CARTEXELL for Oncology Cell Therapies

PHILADELPHIA—Integral Molecular, the industry leader in discovering antibodies against complex membrane protein targets, has licensed a panel of monoclonal antibodies (MAbs) to CARTEXELL, enabling […]

Published by

FDA Accepts Integral Molecular’s Letter of Intent (LOI) on Membrane Proteome Array Antibody Specificity Test Into ISTAND Drug Development Tools Pilot Program

PHILADELPHIA—Integral Molecular, the leader in antibody discovery against membrane proteins, has been accepted into the U.S. Food & Drug Administration (FDA)’s ISTAND pilot program. […]

Author: admin

A Shot in the Arm for Flu Research: Integral Molecular Introduces Off-the-Shelf Reagents to Evaluate 2023/2024 Influenza Vaccine Efficacy

Genetic Engineering and Integral Molecular Present – Specificity Testing of Antibody and CAR-T Cell Therapies for IND Using the Membrane Proteome Array

Integral Molecular Opens New Research Center in Philadelphia Encompassing Pandemic Preparedness Laboratories

Integral Molecular Reveals Mechanism Underlying Exquisite Specificity of Claudin 6 Therapeutic Antibody Being Developed for Solid Tumors

Integral Molecular Partnership: Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors

Integral Molecular Launches New Product Lines of Safe Reporter Viruses for Vaccine Development and Pandemic Preparedness

Genetic Engineering and Integral Molecular Present – Reporter Virus Tools to Combat Current Viral Threats and the Next Pandemic

Integral Molecular Licenses Claudin 18.2 Monoclonal Antibodies to CARTEXELL for Oncology Cell Therapies

FDA Accepts Integral Molecular’s Letter of Intent (LOI) on Membrane Proteome Array Antibody Specificity Test Into ISTAND Drug Development Tools Pilot Program

Quick Links

Solutions

Contact Us